A Phase I/II Trial of Intrathecal Delivery of Amniotic Fluid Stem Cells for Primary and Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Progressive
Enrolment: 0 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Multiple Sclerosis, Progressive
Enrolment: 0 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Superior mesenteric artery occlusion for 90 minutes followed by reperfusion, causing intestinal ischaemia-reperfusion injury; complemented by hypoxia-induced damage in intestinal organoids
AFSC migrated preferentially to the ileum via the circulation and reduced ileal injury, inflammation and oxidative stress at 48 hours. These effects depended on TSG-6 secretion, and recombinant TSG-6 alone protected intestinal organoids against hypoxia-induced epithelial damage and attenuated intes…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
Model: Streptozotocin-induced beta-cell injury and type 1 diabetes (streptozotocin 50 mg/kg body weight intraperitoneally on 3 consecutive days, mice fasted 4 hours before each injection)
AFSC injection protected against beta-cell damage and increased beta-cell regeneration in a subset of mice, indicated by glucose and insulin levels, increased islet mass and preserved islet structure. Beta-cell preservation and regeneration correlated with activation of the insulin receptor/PI3K/Ak…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.